Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1001 in Advanced Solid Tumors
NCT03744403Phase 1Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sugemalimab in solid tumor, sponsored by CStone Pharmaceuticals. Primary endpoint: Number of participants with adverse events up to 2 years. Started Dec 2018; status: completed.
02
Drugs
sugemalimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03744403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744403.